Eli Lilly, Novo Nordisk Stocks Rise on Reported $149 Obesity Drug Deal with White House
Eli Lilly and Company (NYSE:LLY) shares are in the spotlight following reports indicating the company is close to finalizing a White House agreement to provide its lowest-dose obesity medications at $149 per month, which could open the door to Medicare coverage and broader reimbursement options.
Benzinga ·